Innovative prevention measure for ventilator-associated pneumonia reaches next stage Use of cold plasma can prevent tens of thousands of deaths in Germany alone Study led by expert from the renowned research network BREATH, Hortense Slevogt PINNEBERG
PINNEBERG, Germany -- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for approval as a therapy. Read More
